These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29260607)

  • 61. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tofacitinib for polyarteritis nodosa: a tailored therapy.
    Rimar D; Alpert A; Starosvetsky E; Rosner I; Slobodin G; Rozenbaum M; Kaly L; Boulman N; Awisat A; Ginsberg S; Zilber K; Shen-Orr SS
    Ann Rheum Dis; 2016 Dec; 75(12):2214-2216. PubMed ID: 27558986
    [No Abstract]   [Full Text] [Related]  

  • 63. Successful targeted treatment of mast cell activation syndrome with tofacitinib.
    Afrin LB; Fox RW; Zito SL; Choe L; Glover SC
    Eur J Haematol; 2017 Aug; 99(2):190-193. PubMed ID: 28382662
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
    Feldman SR; Thaçi D; Gooderham M; Augustin M; de la Cruz C; Mallbris L; Buonanno M; Tatulych S; Kaur M; Lan S; Valdez H; Mamolo C
    J Am Acad Dermatol; 2016 Dec; 75(6):1162-1170.e3. PubMed ID: 27692733
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
    Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
    Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
    Bannwarth B; Kostine M; Poursac N
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
    Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
    J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W;
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677
    [TBL] [Abstract][Full Text] [Related]  

  • 69. First Oral Drug for Moderate-To-Severe Ulcerative Colitis.
    Aschenbrenner DS
    Am J Nurs; 2018 Sep; 118(9):22-23. PubMed ID: 30138199
    [No Abstract]   [Full Text] [Related]  

  • 70. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
    Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
    Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
    Merola JF; Elewski B; Tatulych S; Lan S; Tallman A; Kaur M
    J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
    J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
    Abe M; Nishigori C; Torii H; Ihn H; Ito K; Nagaoka M; Isogawa N; Kawaguchi I; Tomochika Y; Kobayashi M; Tallman AM; Papp KA
    J Dermatol; 2017 Nov; 44(11):1228-1237. PubMed ID: 28714180
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
    Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
    Valenzuela F; Papp KA; Pariser D; Tyring SK; Wolk R; Buonanno M; Wang J; Tan H; Valdez H
    BMC Dermatol; 2015 May; 15():8. PubMed ID: 25951857
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tofacitinib for the treatment of psoriasis.
    Galluzzo M; D'Adamio S; Servoli S; Bianchi L; Chimenti S; Talamonti M
    Expert Opin Pharmacother; 2016 Jul; 17(10):1421-33. PubMed ID: 27267933
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K; Tanaka Y
    Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Do we need more psoriasis therapies?
    Lebwohl M
    Lancet; 2015 Aug; 386(9993):512-4. PubMed ID: 26051367
    [No Abstract]   [Full Text] [Related]  

  • 79. Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
    Ann Intern Med; 2013 Aug; 159(4):I-26. PubMed ID: 24026272
    [No Abstract]   [Full Text] [Related]  

  • 80. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY; Craiglow BG; Dai F; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.